Background and Objectives: Levothyroxine (L-T4) monotherapy to normalize TSH level might be not sufficient to restore serum free triiodothyronine (fT3) levels in hypothyroid patients. This study aimed to compare the thyroid hormone levels in euthyroid L-T4 treated athyreotic patients and euthyroid healthy control subjects. Materials and Methods: We included 69 euthyroid L-T4 treated athyreotic female patients after total thyroidectomy and radioactive iodine ablation therapy and 90 euthyroid healthy female. Serum fT3 and free thyroxine (fT4) levels were simultaneously measured using two different assay kits (A and B). Results: The serum fT4 level was higher in the athyreotic patients (kit A: p＜0.001, kit B: p=0.046), and the serum fT3 level was higher in control subjects (kit A: p=0.047, kit B: p=0.102). In the control group, the serum fT3 level was stable and not correlated with the TSH level (kit A: tau=−0.10, p=0.18, kit B: tau=−0.06, p=0.40). However, in the patient group, the serum fT3 level was negatively correlated with the TSH level (kit A: tau=−0.22, p=0.012, kit B: tau=−0.31, p＜0.001). All thyroid hormone parameters measured by kit A showed higher area under the curve values than those measured by kit B for distinguishing the patients from the control subjects. Conclusion: The serum fT3 levels in L-T4 treated athyreotic euthyroid patients were significantly lower than and varied from those of euthyroid healthy control subjects. Thus, L-T4 monotherapy might not be appropriate for some athyreotic patients to maintain optimal T3 levels.
Introduction
Hypothyroidism is a common endocrine disorder with a prevalence of 2-3% in the general population. 1, 2) The therapeutic goal for hypothyroidism is to restore clinical and biochemical euthyroidism through adequate thyroid hormone replacement. The standard treatment of hypothyroidism is administration of levothyroxine (L-T4) to normalize the serum TSH level. This approach has been supported by the hypothesis that the deiodinase in peripheral tissues can produce adequate amount of active triiodothyronine (T3) from thyroxine (T4). Physiologically, only 20% of T3 is secreted by the thyroid gland, and 80% is produced by deiodinase from T4 in peripheral tissues.
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Furthermore, L-T4 has long half-life, allowing a once-daily dosing and stable T3 levels. 3, 4) However, recent studies suggested that a significant proportion of patients treated with L-T4 monotherapy have persistent symptoms and complaints despite the normalized serum TSH levels. 1, [5] [6] [7] This could be because the serum T3 levels might not be sufficiently normalized only with peripheral T4-T3 conversion. 8, 9) The serum T3 level might be an important indicator for the treatment of hypothyroidism; however, the guidelines do not recommend measurement of the serum total T3 or free T3 (fT3) levels. 3, 4) The T3 levels vary with circadian changes or other illness, and the performance of assays used to measure the serum T3
level is known to be inadequate. 4) However, recent progress in technologies, measurement of the serum T3 became more accurate.
In this study, we aimed to evaluate differences in thyroid hormone parameters and the relationships of these hormones after L-T4 treatment. We compare thyroid hormone levels between euthyroid L-T4 treated patients after total thyroidectomy and radioactive iodine (RAI) ablation therapy and euthyroid healthy control subjects. Thyroid hormones from patients who underwent total thyroidectomy and radioactive iodine ablation were solely from L-T4 and these patients might be good subjects for analyzing changes in thyroid hormones with L-T4 treatment. The serum free T4 (fT4) and fT3 levels were measured using two assay kits from two different companies for validation.
Materials and Methods

Study Subjects
We retrospectively reviewed medical records of patients who underwent total thyroidectomy and RAI ablation therapy and followed up in Asan Medical
Center between August 2017 and September 2017. 
Results
Subjects Characteristics
Characteristics for the control (n=90) and patient (n=69) are shown in Table 1 . All subjects were female and the median age of patients was 55 years. All subjects showed euthyroidism and the median TSH According to the Kit As, the median fT4, fT3 level and fT3/fT4 ratio of total study subjects was 1.5 ng/dL, 2.8 pg/mL, and 0.19, respectively. Serum fT4 level was significantly higher in patients (p＜0.001).
Serum fT3 level and fT3/fT4 ratio were significantly higher in controls (p=0.047 and p＜0.001). According to the Kit Bs, the median fT4, fT3 level and fT3/fT4 ratio of total study subjects was 1.2 ng/dL, 3.6 pg/mL, and 0.29, respectively. Serum fT4 level was significantly higher in patients (p=0.046) and fT3/fT4 ratio was significantly higher in controls (p=0.009) but, serum fT3 level was not different between groups. Even though fT3 level was lower in patients, all fT3 levels in patients were in the manufacturer's recommended reference range.
When we evaluated ICC values of thyroid hormones according to the kits, serum fT4 levels presented moderate reliability and serum fT3 levels presented good reliability between different kits ( Table 2 ).
Relationship between TSH and Free T3, Free T4, Free T3/Free T4 Ratio
We evaluated the relationship between fT3, fT4, fT3/fT4 ratio and TSH in the control and patient group.
As shown in Fig. 1, fT3 (Table 3) .
When we evaluated the AUC values of fT3, fT4 and fT3/fT4 ratio for discriminating the patient group from the control group in both kits, the Kit As presented higher values than Kit Bs in all thyroid hormone parameters (Table 4 ).
Discussion
In this in-depth analysis of thyroid hormones, we found significant differences in thyroid hormone parameters and the relationships of these hormones between euthyroid L-T4 treated athyreotic patients and euthyroid healthy subjects. Serum fT4 levels were sig-nificantly higher in athyreotic patients than controls.
Conversely, serum fT3 levels were significantly lower in athyreotic patients than controls, which resulted in significantly lower fT3/fT4 ratio in athyreotic patients.
This phenomenon was not different between two different kits. Our results are consistent with previous studies 7, 8, 11) and also suggested that peripheral T3 conversion from T4 might be insufficient for L-T4 treated athyreotic patients to maintain normal T3 levels. 5, 8, 12) The relationship between serum TSH and fT4 or fT3 levels was also different between the patient group and the control group. In euthyroid healthy controls, serum fT3 levels were steady and only serum fT4 levels were inversely correlated with serum TSH level.
However, serum fT3 levels were varied and inversely correlated with serum TSH level in euthyroid L-T4 treated athyreotic patient. These relationships also were not different between two different kits. These findings imply that maintaining stable T3 levels is important for healthy individuals and deiodinase activity might be positively correlated with serum TSH levels to maintain T3 levels in euthyroid healthy subjects as previously reported. 5, 9, 13) In athyreotic euthyroid patients, however, the relationship was not restored even with normal serum TSH levels from sufficient L-T4 treatment. Our findings suggest that L-T4 monotherapy might not be optimal replacement modality for some hypothyroid patients and suggest the possible advantages of low dose liothyronine combination with L-T4. 5, 6, [13] [14] [15] Further well-designed prospective studies are needed to clarify the best management of post-operative hypothyroidism.
In euthyroid healthy subjects, not only fT3 levels, but There are some limitations in this study. First, the number of subjects in this study was small and only females were included in this study. In this study, fT4 in euthyroid athyreotic patients was not related with TSH, which is different from previous studies. 8, 13) This result might be biased due to small number of subjects. Second, we did not measured patient's well-being state or any biochemical parameters suggesting tissue thyroid function. As a result, we could not confirm the clinical significance of low and variable fT3 levels and could not find clinical features associated with low and variable fT3 levels in athyreotic patients. However, our study has an advantage in that we measured free thyroid hormone levels by two different assay kits at the same time. Differences in thyroid hormone parameters between the patients and the controls were similar irrespective of what assay was used and this validated our results.
In conclusion, serum fT3 levels were significantly lower and varied in L-T4 treated athyreotic euthyroid patients than euthyroid healthy controls. These findings suggest that L-T4 monotherapy might not be an appropriate replacement modality for some athyreotic patients to maintain optimal T3 levels. Future studies are needed to find a more physiological treatment for these patients but, our results suggest the possible role of low dose liothyronine combination with L-T4 as a better treatment for them.
